<h3>Objective:</h3> The coronavirus pandemic facilitated widespread implementation of tele-neuropsychological assessment of DBS candidates due to physical distancing and safety requirements. Our prior work has demonstrated preoperative home-to-home TeleNP feasibility and patient satisfaction in determining candidacy for DBS in PD patients. To our knowledge the implementation and feasibility of TeleNP in assessing postoperative outcomes have not been assessed. <h3>Background:</h3> Neurologists work closely with neuropsychologists who evaluate postoperative cognitive, behavioral, and mood outcomes in PD patients. For PD patients with barriers to accessing care, home-to-home TeleNP post-DBS management provides a much-needed resource to increase care access. <h3>Design/Methods:</h3> PD patients [<i>n</i>=28, <i>M</i><sub>age</sub>=62.6(8.8), 75% male, <i>M</i><sub>edu</sub>=16.1(3.0), 46.4% Hispanic, 64.3% pretested in English<b>/</b>35.7% in Spanish, 92.9% STN), underwent pre- and post-cognitive (global cognition, language, memory, attention, processing speed, visuospatial ability) and emotional assessments via home-to-home TeleNP between May 2020 and March 2022. PD patients underwent either in-person (n=23) or TeleNP (n=5) evaluation pre-DBS and in-person (<i>n</i>=1) or home-to-home TeleNP (<i>n</i>=27) assessments post-surgery. Paired t-tests were conducted to assess differences between pre and post assessments. <h3>Results:</h3> To date, 28 candidates completed both pre- and post-DBS neuropsychological assessment. Significant differences in semantic fluency (Animals: <i>t</i>(53)=3.89, <i>d</i>=.53, <i>m</i><i><sub>z-d</sub></i><sub>iff</sub>=0.6), short- and long-delay verbal recall (CVLT: <i>t</i>(43)=2.95, <i>d</i>=.44, <i>m</i><i><sub>z-d</sub></i><sub>iff</sub>=0.4 and <i>t</i>(47)=3.13, <i>d</i>=.45, <i>m</i><i><sub>z-d</sub></i><sub>iff</sub>=0.4 respectively), and processing speed (SDMT: <i>t</i>(23)=3.57, <i>d</i>=.73, <i>m</i><i><sub>z-d</sub></i><sub>iff</sub>=0.8) were noted at <i>p</i><.005 (Bonferroni-adjusted for family-wise error), where <i>m</i><i><sub>z-d</sub></i><sub>iff</sub> represents <i>z</i>-score decrease from pre- to post-test. In contrast, no significant change was noted in orientation, naming, phonemic fluency, working memory, executive functioning, verbal reasoning, depression, anxiety, or PD symptom dysfunction (PDQ-39). <h3>Conclusions:</h3> TeleNP is a feasible platform for comprehensively assessing short- and long-term outcomes in PD patients post-DBS in English and Spanish. Remote care reduces the risk of patients being lost to follow-up by offering time- and cost advantages to those who have physical or transportation limitations or are living in remote areas. <b>Disclosure:</b> Ms. Bullock has nothing to disclose. Dr. Harcourt has nothing to disclose. Dr. Rodriguez has nothing to disclose. Annelly Buré-Reyes has nothing to disclose. Dr. Luca has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Boston Scientific. Dr. Luca has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Signant Health. Jonathan Jagid has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic Inc. The institution of Jonathan Jagid has received research support from Boston Scientific. The institution of Jonathan Jagid has received research support from Medtronic Inc. Bonnie Levin has nothing to disclose. Miss See has nothing to disclose. The institution of Dr. Haq has received research support from NINDS. The institution of Dr. Haq has received research support from the Parkinson’s Foundation. The institution of Dr. Haq has received research support from NIMH. Dr. Haq has a non-compensated relationship as a consultant with Medtronics that is relevant to AAN interests or activities. Dr. Haq has a non-compensated relationship as a consultant with Boston Scientific that is relevant to AAN interests or activities. Dr. Haq has a non-compensated relationship as a consultant with Abbott that is relevant to AAN interests or activities. Dr. Sarno has nothing to disclose.
Read full abstract